CA2427655A1 - Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization - Google Patents
Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization Download PDFInfo
- Publication number
- CA2427655A1 CA2427655A1 CA002427655A CA2427655A CA2427655A1 CA 2427655 A1 CA2427655 A1 CA 2427655A1 CA 002427655 A CA002427655 A CA 002427655A CA 2427655 A CA2427655 A CA 2427655A CA 2427655 A1 CA2427655 A1 CA 2427655A1
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- agonist
- agn
- selective agonist
- selective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
Methods and compositions for the treatment of ocular neovascularization (CNV) and macular degeneration. The invention includes combining laser treatment with administration of a neuroprotectant.
Claims (25)
1) A method for reducing or eliminating a decrease in neurosensory retinal function following laser treatment of chorodial neovascularization (CNV) while maintaining the vascular occlusion therapeutic effect of such therapy, the method comprising the steps: a) administering to a mammal having a CNV a therapeutically effective amount of an alpha receptor agonist, b) subjecting said mammal to laser irradiation of the retinal locus of the CNV; wherein the amount of neurosensory retinal function following steps a) and b) is greater than when said mammal is subjected to step b) without step a).
2) The method of claim 1 wherein the alpha adrenergic receptor agonist is an alpha 2 selective agonist.
3) The method of claim 2 wherein the alpha adrenergic receptor agonist is selected from the group consisting of brinoinidine, clonidine, and para-aminoclonidine.
4) The method of claim 3 in which the alpha adrenergic receptor agonist is brimonidine.
5) The method of claim 2 wherein the alpha 2 selective agonist is an alpha 2B and/or 2C
selective agonist.
selective agonist.
6) The method of claim 3 wherein the alpha 2 selective agonist is an alpha 2B selective agonist.
7) The method of claim 6 in which the alpha 2B
selective agonist is selected from the group consisting of AGN 960, AGN 795 and AGN 923.
selective agonist is selected from the group consisting of AGN 960, AGN 795 and AGN 923.
8) The method of claim 7 in which the alpha 2B
selective agonist is AGN 960.
selective agonist is AGN 960.
9) The method of claim 7 in which the alpha 2B
selective agonist is AGN 795.
selective agonist is AGN 795.
10) The method of claim 7 in which the alpha 2B
selective agonist is AGN 923.
selective agonist is AGN 923.
11) The method of claim 4 wherein the alpha 2 selective agonist is an alpha 2B specific agonist.
12) The method of claim 1 wherein prior to step b) said method comprises: administering to said patient a therapeutically effective amount of a photoactive agent in a manner such that said photoactive agent is present in the CNV during step b).
13) A method of protecting ocular neural tissue from damage caused by electromagnetic irradiation of the retina comprising delivering to a patient's ocular neural tissue an amount of a neuroprotectant compound effective to protect a plurality of ocular neurons from cell death as compared to ocular neuron cell death following such irradiation observed in the absence of the administration of said neuroprotectant.
14) The method of claim 13 wherein said electromagnetic irradiation is laser irradiation.
15) The method of claim 13 wherein said neuroprotectant compound is an alpha adrenergic agonist.
16) The method of claim 13 wherein said alpha adrenergic agonist is an alpha 2 selective agonist.
17) The method of claim 16 wherein said alpha 2 selective agonist is selected from the group consisting of brimonidine, clonidine and para-aminoclonidine.
18) The method of claim 17 wherein said compound is brimonidine.
19) The method of claim 13 wherein said alpha adrenergic receptor agonist is an alpha 2B
and/or alpha 2C selective agonist.
and/or alpha 2C selective agonist.
20) The method of claim 19 wherein said alpha 2B
and/or alpha 2C selective agonist is selected from the group consisting of AGN
960, AGN 795 and AGN 923.
and/or alpha 2C selective agonist is selected from the group consisting of AGN
960, AGN 795 and AGN 923.
21) The method of claim 20 in which the alpha 2B
selective agonist is AGN 960.
selective agonist is AGN 960.
22) The method of claim 20 in which the alpha 2B
selective agonist is AGN 795.
selective agonist is AGN 795.
23) The method of claim 20 in which the alpha 2B
selective agonist is AGN 923.
selective agonist is AGN 923.
24) The method of claim 13 wherein said neuroprotectant compound is administered at a time sufficiently before said electromagnetic irradiation to permit localization within ocular tissue prior to said treatment.
25) The method of claim 13 wherein said neuroprotectant compound is administered following said electromagnetic irradiation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24485000P | 2000-11-01 | 2000-11-01 | |
US60/244,850 | 2000-11-01 | ||
PCT/US2001/046014 WO2002036162A2 (en) | 2000-11-01 | 2001-11-01 | Compositions for treatment of ocular neovascularization and neural injury |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2427655A1 true CA2427655A1 (en) | 2002-05-10 |
CA2427655C CA2427655C (en) | 2011-07-26 |
Family
ID=22924381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2427655A Expired - Fee Related CA2427655C (en) | 2000-11-01 | 2001-11-01 | Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization |
Country Status (10)
Country | Link |
---|---|
US (1) | US20020094998A1 (en) |
EP (1) | EP1353692B1 (en) |
JP (1) | JP4198988B2 (en) |
AT (1) | ATE426413T1 (en) |
AU (3) | AU2002248284A1 (en) |
CA (1) | CA2427655C (en) |
DE (1) | DE60138137D1 (en) |
ES (1) | ES2322030T3 (en) |
HK (1) | HK1059037A1 (en) |
WO (2) | WO2002058730A2 (en) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8256433B2 (en) * | 1999-07-16 | 2012-09-04 | Aradigm Corporation | Systems and methods for effecting cessation of tobacco use |
US20080138399A1 (en) * | 1999-07-16 | 2008-06-12 | Aradigm Corporation | Dual release nicotine formulations, and systems and methods for their use |
US20080138398A1 (en) * | 1999-07-16 | 2008-06-12 | Aradigm Corporation | Dual release nicotine formulations, and systems and methods for their use |
US20080138294A1 (en) * | 1999-07-16 | 2008-06-12 | Igor Gonda | Systems and methods for effecting cessation of tobacco use |
US20030082183A1 (en) * | 2000-11-01 | 2003-05-01 | Wheeler Larry A. | Methods and compositions for treatment of ocular neovascularization and neural injury |
US7753943B2 (en) * | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
US7323485B2 (en) | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7358269B2 (en) | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7276522B2 (en) | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
EP1549305B1 (en) * | 2002-10-08 | 2009-04-22 | Allergan, Inc. | Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of morbus alzheimer and morbus parkinson |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
BR0315931A (en) * | 2002-10-31 | 2005-09-13 | Celgene Corp | Method of treating, preventing or controlling macular degeneration and pharmaceutical composition |
CA2530166A1 (en) * | 2003-03-07 | 2004-09-23 | Randolph D. Glickman | Antibody-targeted photodynamic therapy |
US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US20070224278A1 (en) * | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
AU2005209201B2 (en) | 2004-01-20 | 2010-06-03 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
US7992570B2 (en) * | 2004-04-22 | 2011-08-09 | Light Sciences Oncology, Inc. | Fractionated light PDT therapy for posterior eye disease |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
US8147865B2 (en) * | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
BRPI0510485A (en) | 2004-04-30 | 2007-11-13 | Allergan Inc | biodegradable intravitreal tyrosine kinase inhibitor implants |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
WO2006012521A2 (en) * | 2004-07-22 | 2006-02-02 | Vanda Pharmaceuticals, Inc. | Treatment for ocular disease |
KR20070054213A (en) | 2004-09-24 | 2007-05-28 | 알러간, 인코포레이티드 | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
BRPI0516950A (en) | 2004-09-24 | 2008-09-30 | Allergan Inc | 4- (cyclically condensed methyl) -imidazol-2-thionas acting as alpha2 adrenergic agonists |
JP2008514603A (en) | 2004-09-24 | 2008-05-08 | アラーガン、インコーポレイテッド | 4- (Heteroaryl-methyl and substituted heteroaryl-methyl) -imidazol-2-thiones as α2 adrenergic agonists |
NZ553566A (en) | 2004-09-28 | 2010-11-26 | Allergan Inc | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same |
WO2006057859A1 (en) * | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
US20060223750A1 (en) * | 2005-04-01 | 2006-10-05 | Allergan, Inc. | Agents and methods for enhancing photodynamic therapy |
US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
EP2119439A3 (en) * | 2005-05-17 | 2010-01-27 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor for treating macular degeneration |
US20070167527A1 (en) * | 2006-01-13 | 2007-07-19 | Burke James A | Memantine for the normalization of visual acuity deficits |
ES2329636B2 (en) | 2006-02-17 | 2010-07-26 | Universitat De Valencia, Estudi General (Participa Con El 70%) | USE OF PEDF FACTOR TO INDUCE MOTHER CELLS SELF-RENEWAL |
US8536445B2 (en) * | 2006-06-02 | 2013-09-17 | Emcore Solar Power, Inc. | Inverted metamorphic multijunction solar cells |
US20080102097A1 (en) * | 2006-10-31 | 2008-05-01 | Zanella John M | Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent |
US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
US8470360B2 (en) | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
US8956641B2 (en) * | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
US9610243B2 (en) | 2008-04-18 | 2017-04-04 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US8722079B2 (en) | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
US20090264477A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc., An Indiana Corporation | Beta adrenergic receptor agonists for treatment of pain and/or inflammation |
US8557273B2 (en) * | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
US9132119B2 (en) * | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
US9072727B2 (en) | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
US9132085B2 (en) * | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
US20090263451A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain |
US8629172B2 (en) * | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
US20090263489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation |
US8946277B2 (en) * | 2008-04-18 | 2015-02-03 | Warsaw Orthopedic, Inc. | Clonidine formulations in a biodegradable polymer carrier |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US8420114B2 (en) * | 2008-04-18 | 2013-04-16 | Warsaw Orthopedic, Inc. | Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation |
US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
US8883768B2 (en) | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
US20090264489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation |
GB0811955D0 (en) | 2008-06-30 | 2008-07-30 | Pci Biotech As | Method |
US20100098746A1 (en) * | 2008-10-20 | 2010-04-22 | Warsaw Orthopedic, Inc. | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
US8822546B2 (en) * | 2008-12-01 | 2014-09-02 | Medtronic, Inc. | Flowable pharmaceutical depot |
US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
US8617583B2 (en) * | 2009-07-17 | 2013-12-31 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis |
US8231891B2 (en) * | 2009-07-31 | 2012-07-31 | Warsaw Orthopedic, Inc. | Implantable drug depot for weight control |
CA2776748A1 (en) * | 2009-10-08 | 2011-04-14 | Neurotech Usa, Inc. | Use of pedf in an encapsulated cell-based delivery system |
US20110097375A1 (en) | 2009-10-26 | 2011-04-28 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
BR122017013201B1 (en) | 2009-11-09 | 2018-05-15 | Allergan, Inc. | COMPOSITION FOR STIMULATION OF HAIR GROWTH |
KR102126007B1 (en) | 2010-01-22 | 2020-06-24 | 알러간, 인코포레이티드 | Intracameral sustained release therapeutic agent implants |
US20110182831A1 (en) * | 2010-01-25 | 2011-07-28 | Aradigm Corporation | Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use |
PL2605771T3 (en) * | 2010-08-16 | 2018-10-31 | Allergan, Inc. | Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists |
US20130046003A1 (en) * | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
CN109602691A (en) | 2013-02-15 | 2019-04-12 | 阿勒根公司 | Sustained drug delivery implantation material |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
US5958875A (en) * | 1996-03-29 | 1999-09-28 | The Regents Of The University Of California | Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity |
US6100254A (en) * | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
ATE406914T1 (en) * | 2000-02-10 | 2008-09-15 | Massachusetts Eye & Ear Infirm | PHOTODYNAMIC THERAPY FOR THE TREATMENT OF EYE DISEASES |
CA2403612A1 (en) * | 2000-03-24 | 2001-10-11 | Romulus Kimbro Brazzell | Improved treatment of neovascularization |
US8106038B2 (en) * | 2001-02-15 | 2012-01-31 | Qlt Inc. | Method for reducing or preventing PDT related inflammation |
-
2001
- 2001-10-26 AU AU2002248284A patent/AU2002248284A1/en not_active Abandoned
- 2001-10-26 WO PCT/US2001/051062 patent/WO2002058730A2/en active Application Filing
- 2001-11-01 EP EP01990804A patent/EP1353692B1/en not_active Expired - Lifetime
- 2001-11-01 WO PCT/US2001/046014 patent/WO2002036162A2/en active Application Filing
- 2001-11-01 JP JP2002538971A patent/JP4198988B2/en not_active Expired - Lifetime
- 2001-11-01 CA CA2427655A patent/CA2427655C/en not_active Expired - Fee Related
- 2001-11-01 AT AT01990804T patent/ATE426413T1/en not_active IP Right Cessation
- 2001-11-01 AU AU3056702A patent/AU3056702A/en active Pending
- 2001-11-01 ES ES01990804T patent/ES2322030T3/en not_active Expired - Lifetime
- 2001-11-01 US US09/998,718 patent/US20020094998A1/en not_active Abandoned
- 2001-11-01 AU AU2002230567A patent/AU2002230567B2/en not_active Ceased
- 2001-11-01 DE DE60138137T patent/DE60138137D1/en not_active Expired - Lifetime
-
2004
- 2004-03-15 HK HK04101890.5A patent/HK1059037A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2322030T3 (en) | 2009-06-16 |
US20020094998A1 (en) | 2002-07-18 |
DE60138137D1 (en) | 2009-05-07 |
EP1353692B1 (en) | 2009-03-25 |
ATE426413T1 (en) | 2009-04-15 |
EP1353692A2 (en) | 2003-10-22 |
WO2002058730A3 (en) | 2003-05-15 |
AU3056702A (en) | 2002-05-15 |
AU2002230567B2 (en) | 2007-01-18 |
WO2002036162A3 (en) | 2003-08-21 |
JP2004512378A (en) | 2004-04-22 |
HK1059037A1 (en) | 2004-06-18 |
AU2002248284A1 (en) | 2002-08-06 |
JP4198988B2 (en) | 2008-12-17 |
WO2002036162A2 (en) | 2002-05-10 |
WO2002058730A2 (en) | 2002-08-01 |
CA2427655C (en) | 2011-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2427655A1 (en) | Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization | |
Larsen et al. | Involvement of adenosine in retinal ischemia. Studies on the rat. | |
Bartley | Acquired lacrimal drainage obstruction: an etiologic classification system, case reports, and a review of the literature. Part 2 | |
Harbour et al. | Pars plana vitrectomy for chronic pseudophakic cystoid macular edema | |
JP4975440B2 (en) | Improvement of macular degeneration and other ophthalmic diseases | |
Lemor et al. | Oral colchicine for the treatment of experimental traction retinal detachment | |
JPH10507743A (en) | Methods and means for drug administration | |
CA2849366A1 (en) | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism | |
JP2006524185A5 (en) | ||
CA2582316A1 (en) | Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases | |
Schwartz et al. | Collagen shield delivery of amphotericin B | |
US7638516B2 (en) | Agent for therapeutic treatment of optic nerve diseases and the like | |
CA3010279A1 (en) | Compositions for the treatment of presbyopia | |
DE60013126T2 (en) | OPHTHALMIC HISTAMINE-CONTAINING COMPOSITIONS AND THEIR USE | |
US6462066B2 (en) | Method and composition for treatment of ischemic neuronal reperfusion injury | |
JPH08511024A (en) | Methods and compositions for reducing intraocular pressure | |
CN107412211A (en) | Aminoadamantan amine single nitric acid ester type compound ophthalmic composition and its preparation and application | |
US4444787A (en) | Ophthalmic topical use of collagen cross-linking inhibitors | |
WO2000021531A1 (en) | Remedies for ocular diseases | |
WO2009039356A1 (en) | Treatment methods with brimonidine | |
Jay et al. | Effect of digital massage on intraocular pressure and ocular and optic nerve blood flow | |
Hong et al. | Ocular hypotensive effects of topically administered agmatine in a chronic ocular hypertensive rat model | |
JP2011144111A (en) | Axial myopia-preventing or treating agent | |
Duan et al. | Preliminary study of a controllable device for subtenon drug infusion in a rabbit model | |
Jay et al. | Effect of Honan intraocular pressure reducer on ocular and optic nerve blood flow in phakic rabbit eyes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20161101 |